These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26254722)

  • 1. Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.
    Banerji JS; Wolff EM; Massman JD; Odem-Davis K; Porter CR; Corman JM
    J Urol; 2016 Jan; 195(1):66-73. PubMed ID: 26254722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.
    Zakaria AS; Dragomir A; Brimo F; Kassouf W; Tanguay S; Aprikian A
    BMC Urol; 2018 Aug; 18(1):69. PubMed ID: 30126402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates.
    Bhindi B; Mamdani M; Kulkarni GS; Finelli A; Hamilton RJ; Trachtenberg J; Zlotta AR; Evans A; van der Kwast TH; Toi A; Fleshner NE
    J Urol; 2015 May; 193(5):1519-24. PubMed ID: 25481037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes observed in prostate biopsy practices in an inner city hospital with a high risk patient population following the 2012 uspstf psa screening recommendations.
    Tam AW; Khusid J; Inoyatov I; Becerra AZ; Davila J; Chouhan JD; Weiss JP; Hyacinthe LM; McNeil BK; Winer AG
    Int Braz J Urol; 2018; 44(4):697-703. PubMed ID: 29617073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.
    Gejerman G; Ciccone P; Goldstein M; Lanteri V; Schlecker B; Sanzone J; Esposito M; Rome S; Ciccone M; Margolis E; Simon R; Guo Y; Pentakota SR; Sadeghi-Nejad H
    Investig Clin Urol; 2017 Nov; 58(6):423-428. PubMed ID: 29124241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
    Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
    Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.
    Cohn JA; Wang CE; Lakeman JC; Silverstein JC; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    Urol Oncol; 2014 Jan; 32(1):41.e23-30. PubMed ID: 23911680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
    Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
    Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.
    Barocas DA; Mallin K; Graves AJ; Penson DF; Palis B; Winchester DP; Chang SS
    J Urol; 2015 Dec; 194(6):1587-93. PubMed ID: 26087383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.
    Squiers LB; Bann CM; Dolina SE; Tzeng J; McCormack L; Kamerow D
    Am J Prev Med; 2013 Aug; 45(2):182-9. PubMed ID: 23867025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Changes in Prostate Cancer Screening Practices and Epidemiology.
    Lee DJ; Mallin K; Graves AJ; Chang SS; Penson DF; Resnick MJ; Barocas DA
    J Urol; 2017 Dec; 198(6):1230-1240. PubMed ID: 28552708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
    Eapen RS; Herlemann A; Washington SL; Cooperberg MR
    Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update.
    Vetterlein MW; Dalela D; Sammon JD; Karabon P; Sood A; Jindal T; Meyer CP; Löppenberg B; Sun M; Trinh QD; Menon M; Abdollah F
    Urology; 2018 Feb; 112():56-65. PubMed ID: 29056579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic prostate cancer incidence in Australia after amendment to prostate-specific antigen screening guidelines.
    Smith S; Wolanski P
    ANZ J Surg; 2018; 88(7-8):E589-E593. PubMed ID: 29194902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer screening practices and diagnoses in patients age 50 and older, Southeastern Michigan, pre/post 2012.
    Rezaee ME; Ward CE; Odom BD; Pollock M
    Prev Med; 2016 Jan; 82():73-6. PubMed ID: 26592690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate Cancer Characteristics in the US Preventive Services Task Force Grade D Era: A Single-Center Study and Meta-Analysis.
    Clements MB; Abdalla B; Culp SH; Costabile RA; Krupski TL
    Urol Int; 2020; 104(9-10):692-698. PubMed ID: 32759606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
    Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
    BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2012 Jul; 157(2):120-34. PubMed ID: 22801674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National Trends in Prostate Biopsy and Radical Prostatectomy Volumes Following the US Preventive Services Task Force Guidelines Against Prostate-Specific Antigen Screening.
    Halpern JA; Shoag JE; Artis AS; Ballman KV; Sedrakyan A; Hershman DL; Wright JD; Shih YC; Hu JC
    JAMA Surg; 2017 Feb; 152(2):192-198. PubMed ID: 27806151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.